title: Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.
abstract: BACKGROUND
  The utility of chemotherapy for women who experience a locoregional recurrence after primary treatment of early breast cancer remains an open question. An international collaborative trial is being conducted by the Breast International Group (BIG), the International Breast Cancer Study Group (IBCSG), and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to determine the effectiveness of cytotoxic therapy for these patients, either alone or in addition to selective use of hormonal therapy and trastuzumab.
  
  
  METHODS
  The trial population includes women who have had a previous diagnosis of invasive breast cancer treated by mastectomy or breast-conserving surgery, but subsequently develop an isolated local and/or regional ipsilateral invasive recurrence. Excision of all macroscopic tumor without evidence of systemic disease is required for study entry. Patients are randomized to receive chemotherapy or no chemotherapy; type of chemotherapy is not protocol-specified. Radiation, hormonal therapy, and trastuzumab are given as appropriate. The primary endpoint is disease-free survival (DFS). Quality-of-life measurements are collected at baseline, and then at 9 and 12 months. The accrual goal is 977 patients.
  
  
  RESULTS
  This report describes the characteristics of the first 99 patients. Sites of recurrence at study entry were: breast (56%), mastectomy scar/chest wall (35%), and regional lymph nodes (9%). Two-thirds of patients have estrogen-receptor-positive recurrences.
  
  
  CONCLUSIONS
  This is the only trial actively investigating the question of "adjuvant" chemotherapy in locally recurrent breast cancer. The case mix of accrual to date indicates a broad representation of this patient population.
authors.affiliation: National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistics Center, Pittsburgh, PA, USA, wapnir@stanford.edu
authors.forename: Irene L
authors.initials: IL
authors.lastname: Wapnir
authors.forename: Stefan
authors.initials: S
authors.lastname: Aebi
authors.forename: Shari
authors.initials: S
authors.lastname: Gelber
authors.forename: Stewart J
authors.initials: SJ
authors.lastname: Anderson
authors.forename: István
authors.initials: I
authors.lastname: Láng
authors.forename: André
authors.initials: A
authors.lastname: Robidoux
authors.forename: Eleftherios P
authors.initials: EP
authors.lastname: Mamounas
authors.forename: Norman
authors.initials: N
authors.lastname: Wolmark
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D013629:Tamoxifen; D000068878:Trastuzumab
references.citation: J Clin Oncol. 2006 May 1;24(13):2028-37
references.pmid: 16648502
references.citation: Schweiz Med Wochenschr. 1988 Dec 31;118(52):1976-81
references.pmid: 3217778
references.citation: Cancer. 1993 Mar 1;71(5):1774-9
references.pmid: 8448741
references.citation: Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):299-310
references.pmid: 2061107
references.citation: J Clin Oncol. 1994 Oct;12(10):2071-7
references.pmid: 7931476
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1205-13
references.pmid: 12663706
references.citation: Clin Breast Cancer. 2008 Jun;8(3):287-92
references.pmid: 18650162
references.citation: Eur J Cancer. 2005 Nov;41(17):2637-44
references.pmid: 16115758
references.citation: J Clin Oncol. 1996 Jan;14(1):52-7
references.pmid: 8558220
references.citation: Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):293-8
references.pmid: 2061106
references.citation: Cancer. 1977 May;39(5):1981-3
references.pmid: 322847
references.citation: Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):833-42
references.pmid: 2170305
references.citation: Lancet. 2000 May 20;355(9217):1757-70
references.pmid: 10832826
references.citation: J Clin Oncol. 1993 Jan;11(1):44-8
references.pmid: 8418240
references.citation: Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):853-63
references.pmid: 9128962
references.citation: Breast Cancer Res Treat. 1997 Sep;45(2):181-92
references.pmid: 9342443
references.citation: Br J Cancer. 1998 Mar;77(6):985-91
references.pmid: 9528845
references.citation: Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):765-75
references.pmid: 7860387
references.citation: Int J Radiat Oncol Biol Phys. 1992;23(2):285-91
references.pmid: 1587748
references.citation: Ann Surg. 1990 Aug;212(2):166-72
references.pmid: 2198001
references.citation: Eur J Surg Oncol. 1987 Oct;13(5):425-8
references.pmid: 3666158
references.citation: Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):74-80
references.pmid: 11516854
references.citation: Breast Cancer Res Treat. 1998 May;49(1):69-78
references.pmid: 9694613
references.citation: Cochrane Database Syst Rev. 2001;(4):CD002195
references.pmid: 11687148
references.citation: Ann Oncol. 2003 Aug;14(8):1215-21
references.pmid: 12881382